Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Harrow Inc HROW

Healthcare Biotechnology
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America... see more

Recent & Breaking News (NDAQ:HROW)

Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients

Business Wire 7 days ago

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Business Wire March 27, 2025

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

Business Wire March 27, 2025

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL

Business Wire March 24, 2025

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Business Wire March 17, 2025

Harrow Launches VEVYE® Access for All

Business Wire March 17, 2025

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

Business Wire March 11, 2025

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

Business Wire March 3, 2025

Harrow Partners with Cencora to Launch "Harrow Cares" Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

Business Wire January 27, 2025

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

Business Wire January 7, 2025

Harrow's ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

Business Wire November 21, 2024

Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery

Business Wire November 20, 2024

Harrow Announces Participation in Upcoming Investor Conferences

Business Wire November 15, 2024

Harrow Announces Third Quarter 2024 Financial Results

Business Wire November 13, 2024

Harrow Launches Access and Affordability Program with Price Reductions for Branded Products

Business Wire November 13, 2024

Harrow Announces Market Access Wins for VEVYE®

Business Wire November 12, 2024

Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow's Branded Eyecare Products

Business Wire November 7, 2024

Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024

Business Wire October 31, 2024

Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery

Business Wire October 10, 2024

Harrow Relaunches TRIESENCE®

Business Wire October 3, 2024